Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage. This is an ASCO Meeting Abstract ...
There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...
If you or a loved one has prostate cancer, you may be interested in learning about medicines used to treat it. One option is a medicine called Erleada (apalutamide). The FDA approved Erleada in 2018.
High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and ...
Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...
8.9% of patients on combo had little to no cancer at surgery vs 1% on hormone therapy alone Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J ...
Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results